Inna Thalmann

VC Investor at Breega | Mable (YC S21)

Co-founder

Mable· Summer 2021🇬🇧 London Area, United Kingdom

in LinkedIn

2025YC Alumni Partner· Founder Factor

Founder · since 2018

Company

Founder Factor

Role

YC Alumni Partner

current

Stage

—

no public source

Raised

—

no public source

Based

—

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Mable

First personalized migraine clinic using genetics and telehealth.

Summer 2021

Experience

Career

BREEGA
VC Investor · London Area, United Kingdom · 2025 – Present
2025
Founder Factor
YC Alumni Partner · 2025 – Present
2025
University of Oxford
Postdoctoral Fellow · Oxford, England, United Kingdom · 2022 – 2025
2022
redalpine
VC Investor · London Area, United Kingdom · 2023 – 2025
2023
Mable | Neurolytic Healthcare
Co-founder
Co-Founder, COO · San Francisco, California, United States · 2018 – 2023
2018
University of Oxford
PhD (DPhil) Researcher in Health Economics, Econometrics · Oxford, United Kingdom · 2017 – 2021
2017
LSE Department of Health Policy
Public Policy Consultant · London Area, United Kingdom · 2016 – 2017
2016
Deloitte
Market Access & HEOR Trainee · Brussels Area, Belgium · 2016
2016
The London School of Economics and Political Science (LSE)
Research Assistant · London Area, United Kingdom · 2015 – 2016
2015
OECD - OCDE
Intern · Paris Area, France · 2014
2014

Bio

Inna is Co-Founder and COO of Mable - a precision medicine company using whole genome sequencing to optimise prescribing decisions. Prior to this, Inna completed her PhD in Econometrics with a focus on Health Economics at the University of Oxford, followed by postdoctoral research focused on the development of novel phenotype algorithms to increase the cost-efficiency of clinical trials.